A 2-Week Course of Enteral Treatment with a Very Low-Calorie Protein-Based Formula for the Management of Severe Obesity
| Autor: | Paolo Sorrentino, Luigi Monaco, Giuseppe Castaldo, Laura Castaldo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pediatrics
medicine.medical_specialty lcsh:RC648-665 Article Subject Endocrine and Autonomic Systems business.industry Endocrinology Diabetes and Metabolism Low calorie Severe obesity Body weight lcsh:Diseases of the endocrine glands. Clinical endocrinology Enteral administration chemistry.chemical_compound Endocrinology chemistry Weight loss Clinical Study Uric acid Medicine medicine.symptom Adverse effect business Body mass index |
| Zdroj: | International Journal of Endocrinology, Vol 2015 (2015) International Journal of Endocrinology |
| ISSN: | 1687-8345 1687-8337 |
| Popis: | Background. Multiple weight loss failures among obese patients suggest the design of new therapeutic strategies. We investigated the role of 2-week course of enteral treatment with a very low-calorie protein-based formula in the management of severe obesity.Methods. We evaluated the feasibility, safety, and efficacy of 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube in severely obese adults (body mass index (BMI) ≥ 40 kg/m2).Results. In total, 364 patients (59% women; BMI =46.6±7.2 kg/m2) were recruited. The intervention was discontinued within 48 hours in 26 patients, due to nasogastric tube intolerance. No serious adverse events occurred. During the first and the second week, 65% and 80% patients, respectively, reported no side effects. All biochemical safety parameters were affected by the intervention, particularly uric acid (+45%) and aminotransferases (+48%). In the other cases the change was negligible. We observed significant weight loss (5.7±2.3%) and improvement in blood pressure and glucose and lipid metabolism parameters (P<0.001).Conclusions. A 2-week course of enteral treatment with a very low-calorie protein-based formula appeared a feasible, likely safe, and efficacious therapeutic option to be considered for inclusion into a composite weight loss program for the management of severe obesity. This trial is registered with ClinicalTrials.gov Identifier:NCT01965990. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|